Skip navigation
Universidade Federal da Bahia |
Repositório Institucional da UFBA
Use este identificador para citar ou linkar para este item: https://repositorio.ufba.br/handle/ri/43917
Registro completo de metadados
Campo DCValorIdioma
dc.creatorDamasceno, Elder Trindade-
dc.date.accessioned2026-01-28T14:55:04Z-
dc.date.available2026-01-28T14:55:04Z-
dc.date.issued2022-11-23-
dc.identifier.urihttps://repositorio.ufba.br/handle/ri/43917-
dc.description.abstractChronic kidney disease (CKD) is a worldwide relevant public health problem, with early cardiovascular disease (CVD) as the most cause of death. Disorders in lipoprotein metabolism are associated with CVD increasing, which makes it imperative to advance in lipoprotein structure and functionality studies, especially for high-density lipoprotein (HDL), as it acts in the reverse cholesterol transport and has cardioprotective, antioxidant, and anti-inflammatory properties, very important aspects in patients with CKD. This study aimed to evaluate HDL structural modifications in patients with CKD undergoing renal replacement therapy (RRT), hemodialysis, before and after kidney transplantation. This study included 50 patients with CKD undergoing hemodialysis before and after four months of kidney transplantation. Biochemical analyses were performed by reflectance, HDL particle size, and polydispersity by the light scattering method and the Apo-AI and Apo-B by turbidimetry. Significant increases were found among total cholesterol, non-HDL cholesterol, and LDL-c concentrations after transplantation. For Apo-B and the ApoB/Apo A-I ratio, we observed a significant increase after transplantation only in men. C-reactive protein was significantly lower after transplantation. No significant differences were found in HDL particle size before and after kidney transplantation. However, when analyzing the HDL particles polydispersities, the dispersion was lower after transplantation. The study findings showed significant differences in lipid metabolism before and after kidney transplantation. To properly assess the findings and their possible influence as a condition that increases cardiovascular risk, it will be necessary to develop more in-depth HDL structure and functionality studies, mainly considering the type of study design to reach the appropriate goals intended to be evaluated.pt_BR
dc.description.sponsorshipAperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES)pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal da bahiapt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectDoença renal crônicapt_BR
dc.subjectUremiapt_BR
dc.subjectDoenças cardiovascularespt_BR
dc.subjectTransplante renalpt_BR
dc.subjectDislipidemiapt_BR
dc.subjectLipoproteína de alta densidadept_BR
dc.subjectFarmáciapt_BR
dc.subjectBioquímicapt_BR
dc.subjectInsuficiência renal crônicapt_BR
dc.subjectLipoproteínaspt_BR
dc.subjectRins - Transplantept_BR
dc.subjectSistema cardiovascular - Doençaspt_BR
dc.subject.otherChronic kidney diseasept_BR
dc.subject.otherUremiapt_BR
dc.subject.otherCardiovascular diseasept_BR
dc.subject.otherKidney transplantationpt_BR
dc.subject.otherDyslipidemiapt_BR
dc.subject.otherHigh-density lipoproteinpt_BR
dc.titleAvaliação da lipoproteína de alta densidade em pacientes com doença renal crônica em terapia substitutiva: antes e após o trasnplante renalpt_BR
dc.title.alternativeEvaluation of high-density lipoprotein in patients with chronic kidney disease undergoing replacement therapy: before and after kidney transplantationpt_BR
dc.typeDissertaçãopt_BR
dc.publisher.programPrograma de Pós-Graduação em Farmácia (PPGFAR) pt_BR
dc.publisher.initialsUFBApt_BR
dc.publisher.countryBrasilpt_BR
dc.subject.cnpqCNPQ::CIENCIAS DA SAUDE::FARMACIA::ANALISE TOXICOLOGICApt_BR
dc.contributor.advisor1Couto, Ricardo David-
dc.contributor.advisor1IDhttps://orcid.org/0000-0003-2119-437Xpt_BR
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/9320666442334093pt_BR
dc.contributor.advisor-co1Bidu, Nadielle Silva-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/8585220777199895pt_BR
dc.contributor.referee1Couto, Ricardo David-
dc.contributor.referee1IDhttps://orcid.org/0000-0003-2119-437Xpt_BR
dc.contributor.referee1Latteshttp://lattes.cnpq.br/9320666442334093pt_BR
dc.contributor.referee2Barbosa, Cynara Gomes-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/1464729909848094pt_BR
dc.contributor.referee3Moura Neto, José Pereira de-
dc.contributor.referee3IDhttps://orcid.org/0000-0003-2177-7292pt_BR
dc.contributor.referee3Latteshttp://lattes.cnpq.br/6749773067557179pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/9782104297067668pt_BR
dc.description.resumoA doença renal crônica (DRC) é um importante problema de saúde pública mundial, tendo as doenças cardiovasculares (DCV) precoces como a principal causa de morte. Os distúrbios no metabolismo das lipoproteínas estão associados ao aumento das DCV, o que torna importante investir em estudos sobre estrutura e funcionalidade das lipoproteínas, principalmente da lipoproteína de alta densidade (HDL), por atuar no transporte reverso do colesterol e ter propriedades cardioprotetoras, antioxidante e anti-inflamatórias, aspectos importantíssimos em pacientes com DRC. O objetivo deste estudo foi avaliar modificações estruturais na HDL de pacientes com DRC em terapia renal substitutiva (TRS), hemodiálise, antes e após o transplante renal. Foram incluídos neste estudo 50 pacientes com DRC em hemodiálise antes e 4 meses após o transplante renal. As análises bioquímicas foram realizadas por reflectância, o tamanho de partícula da HDL e a polidispersidade pelo método por laser light scattering e as Apo-AI e Apo-B por turbidimetria. Foi encontrado aumento significativo entre as concentrações de colesterol total, colesterol não HDL e LDL-c após o transplante. Para a Apo-B e a relação Apo-B/Apo-A-I observamos aumento significativo após o transplante apenas em homens. A proteína C reativa foi significativamente menor após o transplante. Não foram encontradas diferenças significativas no tamanho de partícula da HDL antes e após e o transplante renal. No entanto, quando analisado a polidispersidade das partículas da HDL, a dispersão foi menor após o transplante. Os achados deste estudo mostraram diferenças significativas no metabolismo lipídico antes e pós-transplante renal. Para avaliar apropriadamente os achados e sua possível influência como condição que eleva o risco cardiovascular será necessário desenvolver estudos mais aprofundados sobre a estrutura e funcionalidade da HDL, considerando principalmente tipo de desenho de estudo que seja apropriado ao que se pretende avaliar.pt_BR
dc.publisher.departmentFaculdade de Farmáciapt_BR
dc.relation.referencesALCALDE, P. R; KIRSZTAJN, G. M. Gastos do Sistema Único de Saúde brasileiro com doença renal crônica. J. Bras. Nefrol. 2018, vol.40, n.2, pp.122-129. ALEXANDER M, et. al. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin. 2007;23(12):2997-3008. ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017. Arquivos Brasileiros de Cardiologia. São Paulo: SBC, v. 109, n. 2, ago. 2017. Supl. 1. BARRADOUGH, K. A. et.al. Once-Versus Twice-Daily Tacrolimus. Are the Formulations Truly Equivalent Drugs, v. 71, n. 12, p. 1561 – 1577, 2011. BASADONNA, G. P. et.al. Early versus later acute renal allograft rejection: impact of chronic rejection. Transplantation 1993; 55: 993-995. BASTOS, M. G.; BREGMAN, R.; KIRSZTAJN, G. M. Doença Renal Crônica: frequente e grave, mas também prevenível e tratável. Rev Assoc Med Bras, v. 56, n. 2, p. 248-253, 2010. BATISTA, C. M. M. et. al. Perfil epidemiológico dos pacientes em lista de espera para o transplante renal. Acta Paulista de Enfermagem. 2017, v. 30, n. 3. pp. 280-286. BRASIL, Ministério da Saúde. Protocolos clínicos e diretrizes terapêuticas Anemia na Doença Renal Crônica. Brasília: MS, 2017. CASES, A.; COLL, E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005;(99): S87–S93 CECKA, J. M. Clinical outcome of renal transplantation. Factors influencing patient and graft survival. Surg Clin N A 1998, 78: 133- 148 CECKA, J. M. Early rejection: analyses of the UNOS Scientific Renal Transplant Registry. Clinical Transplants, Los Angeles, p. 577-583, 1991. CECKA, J. M.; YOUNG, W. C.; TERASAKI, P. I. Analyses of the UNOS scientific renal transplant registry at three years: early events affecting transplant success. Transplantation. 1992; 53: 59 CHEN, S. C. et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One. 2013;8(2): e55643. CHEN, X. et al. Plasma PLTP activity is inversely associated with HDL-c levels. Nutricion & Metabolism 2009, 6:49. CHERCHIGLIA M.L. et.al. Gênese de uma política pública de ações de alto custo e complexidade: as terapias renais substitutivas no Brasil. Revista da Associação Médica de Minas Gerais, Belo Horizonte, v. 16, p. 83-89, 2006. COYNE, D. W. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int. 2012;82(2):235-41. DEVINE, P. A; COURTNEY, A. E; MAXWELL, A. P. Risco cardiovascular em receptores de transplante renal. J Nephrol. Junho de 2019; 32 (3): 389-399. ECKARDT K. U. Pathophysiology of renal anemia. Clin Nephrol. 2000;53: Suppl 1: S2-S8. FEINGOLD, K. R. Introduction to Lipids and Lipoproteins, Endotext, South Dartmouth (MA): MDText.com, Inc., 2000. FERRAZ, S. F. et. al. Estado nutricional e ganho de peso interdialítico de pacientes com doença renal crônica em hemodiálise. J Bras Nefrol. 2015;37(3):306-314 FLORENS, N. et al. Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins. Toxins (Basel). 2016;8(12):376. Published 2016 Dec 16. FOUQUE, D. et. al.. Guideline on nutrition. Nephrol Dial Trasnplant. v 22. P.45-87. 2007. FREDJ, N. B. et al. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. Experimental and Clinical Transplantation, v. 4, p. 394 – 400, 2016. GBD Mortality and Causes of Death Collaborators Global, regional, and national age- sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117–171 GILLARD, B. K. et al. Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta. 2009 Dec;1791(12):1125-32. doi: 10.1016/j.bbalip.2009.07.004. GUGLIUCCI, A.; KOTANI, K.; KIMURA, S. Paraoxonase 1 in chronic kidney failure. Journal of Lipids, vol. 2012, Article ID726048, 10 pages, 2012. HOSHINO, J. et al. Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. vol. 30,5 (2020): 404-414. IPEA – INSTITUTO DE PESQUISA ECONÔMICA APLICADA. Desigualdade de Transplante de Órgãos no Brasil: Análise do perfil dos receptores por sexo e raça ou cor. Brasília: Ipea, 2011. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39: Suppl 2: S1-S246. KAYSEN, G. A. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. Jan;19(1):73-7, 2009. KIMURA, T.; ISAKA, Y.; YOSHIMORI, T. Autophagy and kidney inflammation. Autophagy. 2017;13(6):997‐1003. doi:10.1080/15548627.2017.1309485 LAMB, E. J.; LEVEY, A. S.; STEVENS, P. E. The Kidney Disease Improving Global Outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution. Clin Chem 59: 462–465, 2013. doi:10.1373/clinchem.2012.184259. LEVEY, A. S. et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007 Aug; 72(3):247-59. LIABEUF, S. et al. Levels of Indoxyl Sulfate in Kidney Transplant Patients, and the Relationship With Hard Outcomes. Circ J. 2016;80(3):722-30. LIMA, E. S.; COUTO, R. D. Estrutura, metabolismo e funções fisiológicas da lipoproteína de alta densidade. J Bras Patol Med Lab. v. 42, n. 3, p. 169-178, 2006. LIMA, E. S.; MARANHAO, R. C. Rapid, Simple Laser-Light-Scattering Method for HDL Particle Sizing in Whole Plasma. Clin Chemistry, v.50, p.1086-1088, 2004. MARQUES, F. S. et al. Low-Flow Polysulfone Hemodialysis Alters Lipoprotein Parameters, Paraoxonase Activity and in Vitro Incorporation of Phospholipids. Journal of Biophysical Chemistry, 8, 23-38. 2017. https://doi.org/10.4236/jbpc.2017.83003 MARQUES, F; SILVA, A. L; COUTO, R. D. Dislipidemia associada à doença renal crônica – Revisão de literatura. Revista de Ciências Médicas e Biológicas. 13. 220-225, 2014. MIKOLASEVIC, I. et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. International Journal of Nephrology and Renovascular Disease 2017:10 35–45. NATIONAL KIDNEY FOUNDATION. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266. PMID: 11904577. NIIOKA, T. et al. Comparison of Pharmacokinetics and Pharmacogenetics of Once- and Twice-Daily Tacrolimus in the Early Stage After Renal Transplantation. Transplantation, v. 94, n 10, 1013 – 1019, 2012. NUMAKURA, K. et. al. Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation. Dis Markers. 2015;2015:179434. doi: 10.1155/2015/179434. Epub 2015 Apr 6. PMID: 25944971; PMCID: PMC4402561. OLIVEIRA, H. M. et. al. Perfil clínico-epidemiológico dos pacientes em programa crônico de hemodiálise em João Pessoa - PB. Jornal Brasileiro de Nefrologia. 2014, v. 36, n. 3, pp. 367-374. PERES, L. A. B. et al. Estudo epidemiológico da doença renal crônica terminal no oeste do Paraná: uma experiência de 878 casos atendidos em 25 anos. J. Bras. Nefrol. vol.32, n.1, pp. 51-56, 2010. PORT, F. Morbidity and mortality in dialysis patients. Kidney Int 1994; 46:1728-37. REMMERIE, A.; SCOTT, C. L. Macrophages and lipid metabolism. Cell Immunol. 2018; 330:27‐42. RONCHETTI, S. et al. How Glucocorticoids Affect the Neutrophil Life. International journal of molecular sciences. vol. 19,12 4090. 17 Dec. 2018, doi:10.3390/ijms19124090 SARMENTO, L. R. et. al. Prevalence of clinically validated primary causes of end- stage renal disease (ESRD) in a State Capital in Northeastern Brazil. Brazilian Journal of Nephrology [online]. 2018, v. 40, n. 2. SCHUCHARDT, M; TÖLLE, M; VAN DER GIET, M. High-density lipoprotein: structural and functional changes under uremic conditions and the therapeutic consequences. Handb Exp Pharmacol. 2015;224:423-53. SHOENFELD, Y. et al. Prednisone-induced leukocytosis. Influenced of dosage, method and duration of administration on the degree of leukocytosis. Am J Med. 1981;71:773-8. SESSO, R. C. et al. Brazilian Chronic Dialysis Survey 2016. J. Bras. Nefrol. São Paulo, v. 39, n. 3, p. 261-266, Sept. 2017. SPINELLI, G. A. et. al. Lipid Profile Changes During the First Year After Kidney Transplantation: Risk Factors and Influence of the Immunosuppressive Drug Regimen. Transplantation Proceedings,43, 3730 –3737 (2011). TEIXEIRA, R. M. et al. HDL Particle Size and Functionality Comparison between Patients with and without Confirmed Acute Myocardial Infarction. Cardiology research and practice. vol. 2019 3074602. 3 Mar. 2019. THAXTON, C. S. et al. Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv Drug Deliv Rev. 2016;106(Pt A):116‐131. VAZIRI, N. D. Causes of dysregulation of lipid metabolism in chronic renal failure. Seminaris in dialysis. Vol. 22 (6): 644-651, 2009. VAZIRI, N. D. Dislipidemia de insuficiência renal crônica: natureza, mecanismos e consequências potenciais. Am J Physiol Physal Renal 290: F262–272, 2006. VAZIRI, N. D.; NORRIS, K. Distúrbios lipídicos e sua relevância para os resultados na doença renal crônica. Blood Purif 31: 189–196, 2011. WALLDIUS, G.; JUNGNER, I. Apolipoprotein B and apolipoprtein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. Journal Internal Med, v.255, p.188-255, 2004. WAUTIER, M. P. et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE, The American Journal of Physiology, vol. 280, no. 5, pp. E685–E694, 2001. WEN, J. et al. Association of the TG/HDL-C and Non-HDL-C/HDL-C Ratios with Chronic Kidney Disease in an Adult Chinese Population. Kidney Blood Press Res 2017; 42:1141-1154. WOUDBERG, N. J. et al. Pharmacological Intervention to Modulate HDL: What Do We Target? Front Pharmacol. 2018; 8:989, 2018 Jan 22. YANG, H. C; FOGO, A. B.; KON, V. Kidneys: key modulators of high-density lipoprotein levels and function. Curr Opin Nephrol Hypertens. 2016;25(3):174‐179. ZHANG, Q. L; ROTHENBACHER, D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8: 117, 2008. doi:10.1186/1471-2458-8-117. ZHONG, J.; YANG, H. C.; FOGO, A. B. A perspective on chronic kidney disease progression. Am J Physiol Renal Physiol. 2017;312(3):F375‐F384.pt_BR
dc.type.degreeMestrado Acadêmicopt_BR
Aparece nas coleções:Dissertação (PPGFAR)

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Dissertação de Mestrado - Elder Trindade Damasceno.pdfDissertação_Elder Damasceno1,68 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.